Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

27.41 -6.64 (-19.50%)
Delayed Quote Updated: 2:51 PM EST, Nov 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcutis Biotherapeutics, Inc. - Common stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
News headline image
Arcutis (ARQT) Q3 2026 Earnings Call Transcript ↗
Record ZORYVE prescriptions lifted revenue and the full-year outlook. 
Via The Motley Fool
Topics Earnings
News headline image
Arcutis Begins Enrolling Phase 3 Study Evaluating ZORYVE® (roflumilast) Cream 0.3% in Moderate to Severe Atopic Dermatitis
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics Q3 Earnings Call Highlights ↗
Arcutis Biotherapeutics (NASDAQ:ARQT) raised its full-year 2026 net revenue guidance after third-quarter sales of its ZORYVE skin treatments rose 45% from a year earlier, driven primarily by increased... 
Via MarketBeat
Topics Earnings
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Momentum Meets a Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Clears All Eight Growth Rules as Fundamentals Accelerate ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Looks Undervalued as Growth and Margins Support the Value Case ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals ↗
Via Chartmill
News headline image
Arcutis Announces Third Quarter 2026 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Appoints Rob Scott, MD to Board of Directors
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
2 Stocks That Could Soar in Q4 ↗
These growth companies offer investors the potential for near-term upside from fourth-quarter catalysts and long-term growth from realizing value in their pipelines. 
Via The Motley Fool
News headline image
Arcutis Presents ZORYVE® (roflumilast) Data and Real-World Topical Corticosteroid Research at EADV and Fall Clinical
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): Strong Growth Meets a High-Quality Technical Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals ↗
Via Chartmill
News headline image
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance ↗
Via Chartmill
News headline image
Arcutis (ARQT) Q2 2026 Earnings Call Transcript ↗
ZORYVE franchise revenue surged 59% year-over-year, driving profitability. 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability ↗
Watanabe's sale was non-discretionary, executed to cover tax withholding on vesting RSUs. Watanabe retains 950,000+ shares valued at $24.65 million, signaling continued confidence. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcutis Biotherapeutics Q2 Earnings Call Highlights ↗
Arcutis Biotherapeutics (NASDAQ:ARQT) reported second-quarter 2026 net product revenue of $129.9 million, up 59% from the prior-year period and 23% sequentially, as demand for its ZORYVE topical... 
Via MarketBeat
Topics Earnings
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ↗
Via Chartmill
News headline image
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Expands Board of Directors with Appointment of Chris Peetz
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.